Nail dystrophy associated with alopecia areata (AA) and variants alopecia totalis and alopecia universalis (AU) may cause discomfort or pain and limitation of function. Currently, no reliably effective treatment options are available.1 The successful treatment of AA and variants with the oral Janus kinase (JAK) inhibitors tofacitinib, ruxolitinib, and baricitinib2- 4 suggests the possibility that this class of agents may be a therapeutic option for nail dystrophy associated with AA.
Dhayalan A, King BA. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis. JAMA Dermatol. 2016;152(4):492-493. doi:10.1001/jamadermatol.2015.3772